Login
E-mail
Password
Mostra password
Ricorda
Password dimenticata?
Iscriviti gratuitamente
Registrazione
Registrazione
Parametri
Parametri
Quotazioni dinamiche 
OFFON
  1. Home
  2. Azioni
  3. Stati Uniti
  4. Nasdaq
  5. BioAtla, Inc.
  6. Notizie
  7. Altre lingue
    BCAB   US09077B1044

BIOATLA, INC.

(BCAB)
Prezzo in differita. Tempo differito Nasdaq - 25/10 22:00:00
28.38 USD   -0.53%
28/06BIOATLA, INC.: da Roth Capital Partners è Buy
MM
RiassuntoQuotazioniGraficiNotizieRatingAgendaSocietąFinanzaConsensusRevisioniDerivati 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su BIOATLA, INC.
29/09BIOATLA: to Conduct $75 Million Private Placement of Common Stock
29/09BIOATLA: ANNOUNCES PRIVATE PLACEMENT OF 2.7 MILLION SHARES (Form 8-K)
29/09BIOATLA, INC.: Entry into a Material Definitive Agreement, Unregistered Sale of Equity Se..
29/09BIOATLA: Announces Private Placement of 2.7 Million Shares
28/09BioAtla, Inc. announced that it expects to receive $75.0008 million in funding from a g..
16/08BIOATLA: Posts Wider Q2 Loss
13/08BIOATLA: Announces Second Quarter 2021 Financial Results And Provides Clinical Update
13/08BioAtla, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter an..
13/08BIOATLA: Management's Discussion and Analysis of Financial Condition and Results of Opera..
25/06BIOATLA, INC.(NASDAQGM: BCAB) dropped from Russell 2500 Value Index
25/06BIOATLA, INC.(NASDAQGM: BCAB) dropped from Russell 3000E Value Index
25/06BIOATLA, INC.(NASDAQGM: BCAB) dropped from Russell 3000 Value Index
25/06BIOATLA, INC.(NASDAQGM: BCAB) dropped from Russell Small Cap Comp Value Index
25/06BIOATLA, INC.(NASDAQGM: BCAB) dropped from Russell 2000 Value Index
21/06BIOATLA, INC.(NASDAQGM: BCAB) added to S&P Biotechnology Select Industry Index
21/06BIOATLA, INC.(NASDAQGM: BCAB) added to S&P Global BMI Index
17/06BIOATLA, INC.: Submission of Matters to a Vote of Security Holders (form 8-K)
14/06Certain Warrants of BioAtla, Inc. are subject to a Lock-Up Agreement Ending on 14-JUN-2..
14/06Certain Restricted Stock Units of BioAtla, Inc. are subject to a Lock-Up Agreement Endi..
14/06Certain Class B Common Stock of BioAtla, Inc. are subject to a Lock-Up Agreement Ending..
14/06Certain Common stock of BioAtla, Inc. are subject to a Lock-Up Agreement Ending on 14-J..
02/06BIOATLA: Jefferies Conference – June 2021
13/05BIOATLA: Announces First Quarter 2021 Financial Results And Provides Business Update
13/05BioAtla, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter End..
12/05BIOATLA: Management's Discussion and Analysis of Financial Condition and Results of Opera..
12/05BIOATLA: Announces first quarter 2021 financial results and provides business update
07/05HBM boucle l'exercice 2020 sur un bénéfice net record
07/05EQS-ADHOC: HBM Healthcare Investments erzielt im Geschäftsjahr 2020/2021 einen Jahresgewi..
25/03Bioatla, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 202..
24/03BIOATLA: Management's Discussion and Analysis of Financial Condition and Results of Opera..
22/03BIOATLA, INC.(NASDAQGM: BCAB) added to S&P TMI Index
19/03BIOATLA, INC.(NASDAQGM: BCAB) added to Russell 2500 Value-Dynamic Index
19/03BIOATLA, INC.(NASDAQGM: BCAB) added to Russell 2500 Growth-Dynamic Index
19/03BIOATLA, INC.(NASDAQGM: BCAB) added to Russell 2500 Dynamic Index
19/03BIOATLA, INC.(NASDAQGM: BCAB) added to Russell 2000 Growth-Dynamic Index
19/03BIOATLA, INC.(NASDAQGM: BCAB) added to Russell 2000 Value-Dynamic Index
19/03BIOATLA, INC.(NASDAQGM: BCAB) added to Russell 2000 Dynamic Index
19/03BIOATLA, INC.(NASDAQGM: BCAB) added to Russell 3000E Growth Index
19/03BIOATLA, INC.(NASDAQGM: BCAB) added to Russell 2000 Index
19/03BIOATLA, INC.(NASDAQGM: BCAB) added to Russell 2500 Index
19/03BIOATLA, INC.(NASDAQGM: BCAB) added to Russell Small Cap Completeness Index
19/03BIOATLA, INC.(NASDAQGM: BCAB) added to Russell 3000E Index
19/03BIOATLA, INC.(NASDAQGM: BCAB) added to Russell 3000 Growth Index
19/03BIOATLA, INC.(NASDAQGM: BCAB) added to Russell 3000E Value Index
19/03BIOATLA, INC.(NASDAQGM: BCAB) added to Russell 2500 Growth Index
19/03BIOATLA, INC.(NASDAQGM: BCAB) added to Russell 2500 Value Index
19/03BIOATLA, INC.(NASDAQGM: BCAB) added to Russell 3000 Value Index
19/03BIOATLA, INC.(NASDAQGM: BCAB) added to Russell Small Cap Comp Value Index
19/03BIOATLA, INC.(NASDAQGM: BCAB) added to Russell Small Cap Comp Growth Index
19/03BIOATLA, INC.(NASDAQGM: BCAB) added to Russell 2000 Growth Index
19/03BIOATLA, INC.(NASDAQGM: BCAB) added to Russell 3000 Index
19/03BIOATLA, INC.(NASDAQGM: BCAB) added to Russell 2000 Value Index
22/02BioAtla Conditionally Active Biologic Antibody Design And Functionality For Cancer Trea..
09/02BIOATLA, INC.: Change in Directors or Principal Officers (form 8-K)
2020BIOATLA, INC.: Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial..
2020BIOATLA: BioAlta Pockets Extra $28 Million After IPO Underwriters Exercise Over-Allotment..
2020BIOATLA: Announces Closing of Initial Public Offering and Full Exercise of the Underwrite..
2020BIOATLA, INC.(NASDAQGM: BCAB) added to NASDAQ Composite Index
2020BIOATLA: Clinical-Stage Drugmaker BioAtla Soars In Stock Market Debut
2020BIOATLA: Prices $189 Million IPO
2020BioAtla, Inc. has completed an IPO in the amount of $189 million.
2020BioAtla, Inc. has filed an IPO in the amount of $100 million.
2020BioAtla, Inc. Raises $72.5 Million in Series D Financing
2019BioAtla, LLC Appoints Eric Sievers, M.D., as Chief Medical Officer
2019BioAtla ®, LLC Announces That Himalaya Therapeutics SEZC, Has the Exclusive License fro..
2018BioAtla, LLC Announces the Appointment of Scott Smith, as President
2018BioAtla Appoints Lawrence Fong as Scientific Advisor
2018BioAtla, LLC Announces Treatment of the First Patient in its Clinical Trial BA3021-001 ..
2018BioAtla, LLC Announces FDA Clearance of Investigational New Drug Application for CAB-RO..
2018BioAtla, LLC Announces First Patient Treated In Phase1/2 BA3011-001 Clinical Trial For ..
2018BioAtla, LLC Announces FDA Clearance of Investigational New Drug Application for CAB-AX..
2017BioAtla Appoints James Allison and Padmanee Sharma as Scientific Advisors
2017BioAtla And Sinobioway Expand Collaboration Agreement And Enter Into Services Agreement
2017BioAtla, LLC Appoints Yong Ben as Chief Medical Officer
2017BioAtla Joins Forces with F1 Oncology
1  2Pross.
Prossimi eventi del settore